122 results about "Signs and symptoms" patented technology

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators to control neurological state and prevent neurological signs and symptoms. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators to control neurological state and prevent neurological signs and symptoms. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.

Methods for treating Parkinson's disease (PD) are provided. Recombinant adeno-associated virus (rAAV) virions are used to deliver genes encoding dopamine-synthesizing enzymes to the central nervous system of a primate. Once delivered, the genes are expressed, which then results in dopamine synthesis and amelioration in the clinical signs and symptoms of PD. The methods of the present invention can be used to deliver the three central dopamine synthesizing enzymes: tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and guanosine triphosphate cyclohydrolase I thereby enhancing dopamine biosynthesis and providing for enhanced therapeutic efficacy.

Method and system for providing individualized healthcare to a patient having a chronic disease over the Internet are disclosed. The system includes at least a computer server for executing application programs where the computer server includes storage means for storing patient information in at least a database server and means for communicating with at least a patient computer and a medical provider computer. The system further includes means for providing individualized web pages for interacting with the patient, means for monitoring signs and symptoms of the chronic disease using inputs provided by the patient, and means for administrating an individualized treatment of the chronic disease according to the signs and symptoms provided by the patient.

A neurological control system for modulating activity of any component or structure of some or all of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” This system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators to control neurological state or autonomic state and prevent neurological or metabolic signs and symptoms. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals, with sensors configured to sense a particular characteristic indicative of a neurological, psychiatric, or metabolic condition.

A system and method for providing hazardous incident decision support and training includes a user interface component that receives situation definition data, a hazard assessment component and a decision aid. Decision support advice and decision prompts are presented by the system in response to the situation definition interface and hazard assessment. The hazard assessment and expert advice of the system are updated with elapsed time. In another embodiment of the present invention, graphical user interfaces are provided to display a set of menu entries wherein individual menu entries represent a hazardous incident characteristic. The user may select one or more of the menu entries to create a situation definition. Such definitions may be used, for example, to identify a hazardous agent based upon user-inputted signs and symptoms data.

The subject invention relates to the detection, diagnosis and risk stratification of clinical events such as acute coronary syndrome, in patients with signs and symptoms of suspected cardiac origin. In one embodiment, a clinical event in a patient is diagnosed by obtaining the patient's ECG, and at least one in vitro diagnostic assay, preferably an assay for a marker of ischemia, and optionally in vitro diagnostic assays for necrotic markers or other cardiac indicators, and combining the foregoing results in an algorithm to provide a diagnosis or a risk stratification of the clinical condition.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. Methods of manufacture are also provided.

A surveillance system and method for identifying chemical, biological or nuclear attacks or hazards occurring within a large area which combines data derived from a modeling and simulation operation with a surveillance data input. The modeling and simulation operation involves continuous periodic runs of multiple scenarios for various biological, chemical and nuclear agents in various concentrations for a given location. Using real time weather data for each location, a model is made in a database of the effect various concentrations of agents would have at that location and this simulated model is processed. The surveillance data input monitors actual human signs and symptoms for the modeled area. This data with real time weather data is compared with the results of modeling and simulation data for the area to determine if a pattern matching that for any modeled agent is present.

This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies administered through OM, SAS, IVB, IV, and IA routes. An embodiment provides devices for intranasal delivery of therapeutic agents to olfactory mucosal area. Another embodiment uses the technology to deliver the therapeutic, pharmaceutical, biochemical, and biological agents or compounds to the subarachnoid space and ventricular system by using continuous catheters and Ommaya reservoir at the same time. The present method incorporates breaking the blood brain barrier to allow the entry of the anti rabies therapeutic agents into the neuropile. Additionally, an embodiment incorporates cooling of the brain and inducing hibernation to preserve the brain from damage due to rabies.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.

The present invention relates to a novel means to use a fundamental model of the parts of the brain that are dysfunctional in Parkinson's disease, and related dynamical diseases of the brain, as part of a feedback control system to modulate the signs and symptoms of disease. Fundamental computational models that embody our knowledge of the anatomy, neurons, and dynamics of the parts of the brain we wish to control, and use those models to reconstruct what is inaccessible to our measurements. Through emulation the controller synchronizes to the parts of the brain we wish to observe and track. By passing simultaneous control pulses to both the model controller, as well as the brain, we control both the model and the brain. The detailed framework to embed fundamental models of the brain within a control scheme to control symptoms of Parkinsons and related dynamical diseases of the brain are disclosed.

The present invention is directed to methods and compositions of treating or preventing epithelial lining tissue damage from dermatitis or mucositis induced by radiation exposure and/or chemotherapy, by applying to skin, mucosa or other tissues of the body an amount of a therapeutic composition which comprises a histone deacetylase inhibitor formulated with at least one pharmaceutically acceptable biocompatible polymer or carrier, or pharmaceutically acceptable salts in an amount sufficient to delay onset or decrease severity of the signs and symptoms of dermatitis and mucositis in cancer therapy. Such therapeutic compositions have the advantage of prolonged retention and sustained action of the histone deacetylase inhibitor in the skin, mucosa or other tissues of the body. The invention is also directed to treatment and prevention of gastrointestinal distress and cancer-related fatigue syndrome that are associated with mucositis in cancer therapy.

The invention discloses a new traditional Chinese medicine composition for treating the disease of pyelonephritis and a preparation method thereof. The composition mainly comprises the following raw medicines: the root of kudzu vine, gypsum, rhizoma anemarrhenae, phragmites communis, mongolian snakegourd root, cape jasmine, rheum officinale, rehmanniae radix, radix scrophulariae, tree peony bark,honeysuckle, taraxacum officinale root, semen euryales, root-bark of Chinese wolfberry, amur corktree bark, oriental waterplantain rhizome, tuckahoe, belvedere fruit, pyrrosia lingua, cochinchnese asparagus root, plantain seed, ricepaperplant pith, Japanese climbing fern spore, ophiopogon japonicus, the fruit of Chinese magnoliavine, turtle shell, tortoise plastron, cornus officinalis, cherokee rose fruit and cuttlebone. The composition can be prepared into any one common oral preparation according to the conventional traditional Chinese medicine preparation method. The composition can obviously improve the sign and symptom indexes of the patients suffering from pyelonephritis and such symptoms as fever, increase of white blood cells, complications infection, uronephrosis, renal cyst, edema of four limbs, renal function asthenia, urine protein, hematuria and the like, and features confirmed clinical effects, obvious and quick effects. The composition basically combines the medicinal and editable medicines specified in the State Pharmacopoeia, thus having the advantages of low cost and no toxic side effects basically, etc.

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.

The invention is a patch or other applicator, or other method of administration, and a process to concept is to utilize patches (or other methods of delivery), that may contain nicotine in addition to, and that contain other chemicals that have been shown, or will be shown, either by subjective or objective measures, to increase “impact” (an tobacco industry term for the subjective awareness by the smoker of the drug effects of nicotine), or to increase addiction. Chemicals that decrease addiction behavior, or decrease signs and symptoms of withdrawal from the addictive substance or behavior may also be included. The claimed methods have application in the treatment of addiction to tobacco products, addiction to alcohol, and other addictions.

Systemic administration of azithromycin for a period of at least two weeks is effective in ameliorating the signs and symptoms of granulomatous rosacea, a variant form of rosacea that often fails to respond favorably to treatment regimens that are effective against forms of rosacea other than granulomatous rosacea.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.